Is Intra-Cellular Therapies (ITCI) Stock a Solid Choice Right Now? – Tale of the Tape

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical – Biomed/Genetics space as it currently has a Zacks Industry Rank of 55 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Intra-Cellular Therapies is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

In fact, over the past month, current quarter estimates have improved from a loss of 62 cents a share to a loss of 53 cents, while current year estimates have bettered from a loss of $2.56 per share to a loss of $2.34 per share. The company currently carries a Zacks Rank #3 (Hold), which is also a favorable signal.

So, if you are looking for a decent pick in a strong industry, consider Intra-Cellular Therapies. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>